Please assess the completion status of the following clinical trial:

Trial Title: A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Medically healthy~* Male~* Right-handed aged~* 18-45 years~* BMI 17.5 to 35kg/m2.~Exclusion Criteria:~* Females~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of screening and at the time of dosing).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PF-06412562 3mg (Type: EXPERIMENTAL): PF-06412562 3mg BID
- Placebo (Type: PLACEBO_COMPARATOR): Placebo BID
- PF-06412562 15mg (Type: EXPERIMENTAL): PF-06412562 15mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).